FIND YOUR CONSULTANT
JOIN OUR COMMUNITY
FIND YOUR CONSULTANT
JOIN OUR COMMUNITY

Industries > 

Life Sciences > Innovator Pharmaceuticals Practice

Innovator Pharmaceuticals Practice

Umbrex connects companies in innovator pharmaceuticals to independent consultants with deep experience in the industry.

Over 90% of our Innovator Pharmaceuticals Practice consultants are alums of McKinsey, Bain, or BCG.

Finding the right consultant should be this easy.

1

Tell us about your project

2

Interview candidates

(We’ll provide bios within 48 hours on average)

3

Select your consultant and start work!

Find a consultant in our Innovator Pharmaceuticals Practice

Prefer email? Write to [email protected]

Client Segments Umbrex Serves

  • Global small-molecule innovator pharma: Large multinationals with small-molecule-led portfolios; sharpen R&D productivity, BD/M&A, global launch and access, omnichannel commercialization, and LOE/lifecycle value capture.
  • Specialty and rare-disease small-molecule pharma: Mid-cap companies commercializing novel small-molecule therapies in specialty and orphan indications; optimize pricing and access, field effectiveness, patient services, RWE, and international expansion.
  • Clinical-stage small-molecule biopharma: Pre-revenue innovators advancing Phase II/III small molecules; need program strategy, trial design, regulatory, CMC scale-up, launch readiness, partnering, and capital planning.
  • Mature-brand consolidators (Rx small-molecule): Companies acquiring and optimizing established prescription brands; drive lifecycle extensions, pricing and contracting, supply reliability, cost excellence, and digital demand generation.

Selected Capabilities of our Innovator Pharmaceuticals Practice

Strategy & Corporate Development

  • Corporate Strategy And Long-Range Planning: Define enterprise ambition, growth vectors, operating model, and three‑ to five‑year plan for innovator pharmaceuticals; quantify value pools; set scorecards; align investments and performance management.
  • Therapeutic Area And Indication Strategy: Prioritize disease areas and indications using epidemiology, unmet need, and payer dynamics; shape target profiles and evidence plans; focus R&D on differentiated, value‑accretive assets.
  • Portfolio And Capital Allocation: Optimize R&D and launch portfolio via risk‑adjusted net present value and probability of success; rebalance across modalities and geographies; improve ROI, cycle time, and optionality.
  • Mergers Acquisitions And Divestitures Strategy: Originate targets, build theses, and run diligence; size synergies, dis‑synergies, and integration risks; craft deal structures; accelerate accretive growth and portfolio reshaping in innovator pharmaceuticals.
  • Business Development And Licensing: Run search and evaluation, scientific and commercial diligence, valuation, and term‑sheet negotiation; structure options, co‑development, and royalties; strengthen external innovation and fill pipeline gaps.

Operations

  • Manufacturing Excellence And Throughput Uplift: Deploy lean Six Sigma and TPM across drug substance and drug product; increase OEE, yield, batches per week; cut COGS, deviations, changeovers, cycle time.
  • Aseptic Fill-Finish And Sterility Optimization: Redesign line design, behaviors, environmental monitoring (EM), and media fill readiness; raise first-pass sterility, reduce contamination risk, and align with EU Annex 1 and FDA.
  • QC Lab Productivity And Release Cycle Time: Optimize sample planning, scheduling, and right-first-time; enable risk-based review; reduce quality control (QC) cycle time and lot release lead time.
  • Digital Performance Management And Tiered Huddles: Stand up tiered daily management, loss trees, and real-time KPIs; increase accountability, problem-solving speed, and throughput across GMP manufacturing and packaging.
  • Maintenance And Reliability Excellence: Implement reliability-centered maintenance, condition monitoring, and spares optimization on critical assets; reduce unplanned downtime, mean time between failures (MTBF) losses, and maintenance cost per unit.

Supply Chain

  • Network Strategy And Footprint Optimization: Design manufacturing‑to‑market network across internal plants and contract manufacturing organizations (CMOs); optimize footprint, decoupling points, postponement, and regional distribution centers (DCs); reduce cost‑to‑serve, lead time, and risk.
  • Integrated Business Planning And Demand Forecasting: Implement Integrated Business Planning (IBP) linking demand, supply, and finance; include launches, tenders, patient starts, channel data; lift forecast accuracy, on‑time‑in‑full, and inventory turns.
  • Cold Chain And Global Distribution Excellence: Design Good Distribution Practice (GDP) compliant cold chain using validated shippers, risk assessments, and temperature tracking; cut excursions, spoilage, freight cost; improve delivery reliability.
  • Inventory Optimization And Shelf-Life Management: Deploy multi‑echelon inventory optimization with expiry‑aware buffers, minimum order quantity (MOQ) constraints, and allocation rules; cut write‑offs, stockouts, and working capital while sustaining service levels.
  • Supply Risk And Resilience Management: Map supplier and site risks, qualify alternates, set buffers and safety stocks, and build continuity playbooks; increase resilience, supplier reliability, and recovery speed during disruptions.

Procurement & Strategic Sourcing

  • Category Strategy And Sourcing Wave Deployment: Develop category strategies for APIs, excipients, packaging, single‑use assemblies, and lab services; run competitive events; deliver PPV savings, lead‑time reduction, and supply assurance.
  • External Manufacturing Contracting And Commercial Models: Evaluate and contract CDMOs/CMOs for drug substance and drug product; structure pricing, capacity reservations, service levels, and quality agreements; de‑risk tech transfer and accelerate scale‑up.
  • Should-Cost Modeling And Specification Optimization: Build should‑cost models for APIs, filters, vials, stoppers, devices, and secondary packaging; challenge specifications and tolerances; negotiate total cost of ownership reductions.
  • Supplier Risk And Relationship Management: Implement segmentation, risk scoring, audits, corrective actions, and quarterly business reviews; embed scorecards and innovation forums; raise OTIF, quality, resilience, and joint value creation.
  • Procurement Operating Model And Digital Enablement: Redesign procurement organization, category roles, governance, and sourcing playbooks; deploy eSourcing, contract lifecycle management, and spend analytics; increase speed, compliance, and savings capture.

Organization

  • Operating Model And Organizational Design: Redesign therapy- and function-aligned structures across R&D, medical, market access, tech ops, and commercial; clarify decision rights and interfaces; reduce complexity and cycle time.
  • Global Local Governance And Country Clustering: Define region-country clusters, shared services, and governance forums; standardize processes and KPIs; improve focus, scalability, accountability in innovator pharma markets.
  • Talent Strategy And Workforce Planning: Build capability maps, critical roles, and workforce plans across R&D, digital, market access, and quality; optimize spans and layers; reduce vacancies, overtime, and turnover.
  • Leadership, Culture, And Change Enablement: Shape leadership behaviors, operating rhythms, and change management; embed accountability, patient-centricity, and data-driven decisions; accelerate adoption and performance.
  • Incentives And Performance Management: Redesign incentives, KPI hierarchies, and goal cascades aligned to pipeline milestones, launch excellence, and margin; improve goal attainment and cross-functional collaboration.

Marketing

  • Brand And Value Proposition Strategy: Define positioning and messaging for HCP and patient segments; align to label and evidence; increase awareness, consideration, and differentiation in priority therapeutic areas.
  • Launch Excellence And Go-To-Market Planning: Design integrated launch plans—segmentation, journeys, channel mix, field coordination, and congress strategy; sequence readiness; accelerate new-to-brand prescriptions and share ramp across markets.
  • Omnichannel Engagement And CRM Enablement: Build omnichannel strategy across SEO, paid media, social, email, and rep-triggered campaigns; integrate customer relationship management data; lift reach, engagement, and compliant HCP conversions.
  • Content Strategy And MLR Acceleration: Create modular content strategy and medical legal regulatory workflows; enable reuse and localization; reduce review cycle time and increase speed-to-market, consistency, and campaign ROI.
  • Patient Activation And Adherence Programs: Design patient activation and adherence programs—education, onboarding, reminders, and support messaging; integrate patient support hubs; improve initiation, persistence, and refill rates while maintaining privacy compliance.

Pricing

  • Global Price Architecture And Launch Strategy: Set Wholesale Acquisition Cost (WAC), ex‑factory, and net price corridors by indication and channel; sequence markets; integrate payer evidence; maximize price realization and access.
  • Payer Contracting And Rebate Optimization: Design pharmacy benefit manager (PBM), commercial, Medicare, and Medicaid contracts; structure tiers, utilization management, and rebates; protect net price, access, and Medicaid Best Price.
  • Gross-To-Net Optimization And Governance: Build gross‑to‑net (GTN) models and controls across rebates, chargebacks, fees, returns, copay, 340B Drug Pricing Program; improve accrual accuracy, forecast, and earnings quality.
  • International Reference Pricing And Sequencing: Model international reference pricing (IRP) baskets and spillover; set launch sequencing, tender strategy, and price corridors; manage list‑to‑net leakage; safeguard global price and volume.
  • Trade, GPO, And Specialty Channel Pricing: Set wholesaler, group purchasing organization (GPO), and specialty pharmacy pricing, fees, and chargebacks; govern contract stacking; reduce erosion, disputes, and unauthorized discounts.

Finance

  • Advanced FP&A And Scenario Planning: Build driver-based FP&A linking launch curves, patient starts, access, gross‑to‑net (GTN), COGS, and supply; enable scenarios and rolling forecasts; improve predictability and brand margin visibility.
  • Product And Channel Profitability And Cost-To-Serve: Establish true profitability by SKU, indication, customer, and channel; allocate chargebacks, rebates, distribution fees, and services; inform pricing, mix, and customer stratification decisions.
  • Standard Costing And Manufacturing Variance Control: Implement standard costing, routings, and bills; analyze yield, scrap, absorption, purchase price variance; drive COGS transparency, corrective actions, and budget adherence with operations.
  • Working Capital Optimization And Cash Forecasting: Optimize receivables, payables, and inventory; redesign credit terms, deduction management, and slow‑moving and obsolete (SLOB) controls; implement 13‑week cash forecasting; release cash and reduce write‑offs.
  • Capital Allocation Governance And Capex Portfolio Optimization: Set hurdle rates and guardrails; prioritize capex across capacity, quality, and digital; stage‑gate approvals; track benefits; raise return on invested capital and funding speed.

AI, Data & Analytics

  • Data Strategy And Lakehouse Architecture: Define enterprise data model and lakehouse integrating RWD (real‑world data), EHR (electronic health records), CRM, ERP, lab and manufacturing; institute governance and lineage; enable AI.
  • Customer 360 And Next-Best-Action Analytics: Build profiles for healthcare professionals (HCP) and healthcare organizations (HCO) with propensities using machine learning; drive targeting, next‑best‑action, omnichannel optimization; increase reach, conversion, and ROI.
  • Clinical Trial Site Selection And Recruitment Analytics: Predict enrollment, site performance, and screen failures using RWD, investigator history, and geospatial data; optimize feasibility, site mix, and recruitment timelines; reduce trial cycle time.
  • Predictive Quality And Process Analytics: Apply multivariate process control and anomaly detection on batch, sensor, and lab data; predict deviations, optimize parameters, and enable process verification; improve yield and right‑first‑time.
  • MLOps, Model Risk Management, And GxP Validation: Establish lifecycle and documentation for machine learning and LLMs; meet GxP (good practice) validation and Computer Software Assurance; reduce drift, audit findings, and deployment time.

Transformation

  • Enterprise Performance Transformation And EBITDA Uplift: Run diagnostic and cross-functional sprints across manufacturing, quality, supply, and commercial; deliver EBITDA uplift via COGS reduction, SG&A savings, service recovery, and growth acceleration.
  • Transformation Office And Value Capture Management: Stand up a Transformation Office with governance, milestones, benefits tracking, and risk management; enforce cadence and dashboards; accelerate value capture and on-time delivery.
  • Zero-Based Cost And SG&A Simplification: Apply zero-based budgeting, spans and layers redesign, and workflow digitization; eliminate nonvalue work; realize structural SG&A savings, speed, and productivity in innovator pharmaceutical enterprises.
  • Complexity Reduction And Portfolio Streamlining: Quantify cost of complexity across SKUs, packs, labels, and markets; rationalize portfolio and packaging; cut changeovers, inventory, write-offs, and trade spend while protecting revenue.
  • Post-Merger Integration And Carve-Out Execution: Plan and execute integrations or separations; harmonize processes, systems, and commercial policies; protect supply continuity; deliver revenue and cost synergies, Day-1 readiness, and TSA exit.

Compliance

  • Healthcare Compliance Program And Governance: Design compliance program covering Anti-Kickback Statute (AKS), False Claims Act (FCA), interactions, speaker programs, and grants; implement policies, training, monitoring; reduce enforcement risk, audit findings.
  • Promotional Compliance And Review Optimization: Standardize promotional review, claims substantiation, digital and social content monitoring; streamline medical legal regulatory workflows; mitigate off‑label risk, Office of Prescription Drug Promotion (OPDP) actions.
  • Anti-Bribery And Third-Party Risk Management: Build anti‑bribery program aligned to Foreign Corrupt Practices Act (FCPA) and UK Bribery Act; risk‑score and diligence third parties; monitor tenders, payments; reduce corruption exposure.
  • Privacy And Patient Support Compliance: Design privacy governance for patient programs, apps, and analytics aligned to GDPR, CCPA, and HIPAA; embed consent, minimization, and DPIAs; reduce breach risk and penalties.
  • Open Payments And Global Transparency Reporting: Build Open Payments and global disclosure for HCP and HCO transfers of value; strengthen capture, validation, submissions; reduce reporting errors, fines, and reputational risk.

Program & Portfolio Management

  • Portfolio Governance And Prioritization: Establish portfolio governance, standardized stage gates, and business cases; prioritize assets by risk-adjusted value, cost, and constraints; increase throughput, speed, and capital productivity.
  • R&D Program PMO And Stage-Gate Delivery: Run integrated program plans across discovery, preclinical, clinical, chemistry manufacturing controls (CMC), regulatory; improve critical path control, milestone adherence, time to submission, and launch readiness.
  • Resource And Capacity Portfolio Planning: Model constrained people, labs, clinical sites, manufacturing suites, and vendors; optimize sequencing and staffing; cut bottlenecks, overtime, and cycle time; maximize portfolio throughput.
  • Risk, Dependency, And Scenario Management: Implement RAID (risks, assumptions, issues, dependencies) registers and scenario playbooks; standardize mitigations and decision forums; increase predictability, budget adherence, and benefits realization across the portfolio.
  • Launch And Country Rollout Orchestration: Orchestrate cross-market launch plans—labeling, pack readiness, pricing, access, supply cutover; run war rooms; hit submission-to-first-shipment timelines and service levels.

Information Technology

  • ERP Modernization And Order To Cash Digitization: Implement SAP S/4HANA for batch genealogy, serialization, rebates, chargebacks, EDI, ATP; streamline order to cash; improve service, gross‑to‑net accuracy, and close speed.
  • Manufacturing Execution And Electronic Batch Record Enablement: Deploy MES and EBR integrated with equipment and weigh‑dispense; enforce procedures and holds; boost right‑first‑time, release velocity, and audit readiness.
  • Laboratory And Quality Informatics Transformation: Implement LIMS, ELN, LES, and chromatography data systems; integrate instruments; enable ALCOA+ data integrity and Computer Software Assurance; reduce QC cycle time and deviations.
  • Serialization And Track And Trace Compliance: Enable end‑to‑end serialization, aggregation, EPCIS exchange, and verification for DSCSA and EU FMD; improve traceability, diversion control, recall execution, and patient safety.
  • Commercial And Patient Platform Enablement: Deploy Veeva CRM, Vault PromoMats, and patient hub integrations; enable compliant HCP engagement, content reuse, consent, and sample management; increase productivity and speed to market.

Capital Projects

  • Front-End Loading And Basis Of Design: Define URS, process capacity, flows, cleanroom classification, utilities, and Basis of Design; develop Class 3–4 estimates and schedule; de-risk scope, cost, and approvals.
  • EPC/EPCM Partner Strategy And Contracting: Select EPC/EPCM partners; structure target-cost, guaranteed-maximum-price, and incentives; embed safety and quality KPIs; improve cost certainty, schedule adherence, and accountability.
  • CQV Strategy And Risk-Based Validation: Design commissioning, qualification, validation per ASTM E2500; integrate MES/EBR and Computer Software Assurance; compress PPQ timelines and achieve regulatory inspection readiness.
  • Modular, Skid, And Prefabrication Delivery: Deploy modular cleanrooms, process skids, and offsite prefabrication; shorten schedule, improve safety, and de-risk startup for biologics, aseptic fill-finish, and high-potency facilities.
  • Project Controls And BIM-Enabled Delivery: Implement project controls, earned value, risk registers, and Building Information Modeling (BIM) 4D/5D; enable single source of truth; increase predictability, change control, and schedule adherence.

Quality Management Systems

  • Quality System Design And Harmonization: Design and harmonize pharmaceutical quality systems to ICH Q10 and EU/FDA GMP; clarify roles, governance, and SOPs; embed Quality Risk Management and Continued Process Verification.
  • Deviation, CAPA, And Change Control Optimization: Standardize root cause methods, risk ranking, and effectiveness checks; streamline workflows and approvals; deploy metrics and coaching; reduce backlog, recurrence, and cycle time.
  • Data Integrity And Computer Software Assurance: Build ALCOA+ data integrity program; shift from CSV to Computer Software Assurance; remediate audit trails and privileges; cut observations, warning letters, and compliance risk.
  • Supplier And External Manufacturer Quality Management: Establish supplier and CMO/CDMO oversight—segmentation, qualification, audits, and quality agreements; define incoming controls and KPIs; improve OTIF, defect rates, right‑first‑time, and regulatory compliance.
  • Inspection Readiness And Mock Audits: Prepare for FDA, EMA, MHRA inspections; run diagnostics, storyboards, and front‑room/back‑room drills; close gaps; reduce 483s, warning letters, and inspection cycle time.

Regulatory Affairs & Submissions

  • Global Regulatory Strategy And Pathway Design: Define IND (Investigational New Drug), NDA (New Drug Application), BLA, and MAA pathways and accelerated programs; align claims and evidence; de‑risk reviews and compress timelines.
  • Health Authority Engagement And Meeting Readiness: Plan pre‑IND, end‑of‑Phase‑2, and Type B or Type C meetings; craft questions and briefing packages; rehearse; secure alignment and reduce review cycles.
  • Submission Planning And Electronic Dossier Enablement: Build master submission plans, content maps, templates, and reuse libraries; stand up eCTD (electronic Common Technical Document) factory; improve right‑first‑time, quality, and cycle time.
  • Regulatory Information Management And Data Standards: Select and implement RIM (Regulatory Information Management) with IDMP and xEVMPD data models; govern master data; enable traceability, submissions tracking, and inspection readiness.
  • Labeling And Lifecycle Variations Management: Govern CCDS (Company Core Data Sheet), local labels, artwork, and country variations; streamline change control and submissions; accelerate approvals, ensure compliance, and protect supply continuity.

Pharmacovigilance & Safety

  • Pharmacovigilance Operating Model And System Transformation: Design target operating model and implement Oracle Argus or LifeSphere, E2B(R3) gateways, and workflows; improve FAERS/EudraVigilance submission timeliness, data quality, and scalability.
  • Case Intake, Triage, And Processing Optimization: Redesign intake channels, NLP-enabled triage, MedDRA coding, and medical review workflows; cut case cycle time, backlog, and cost per individual case safety report (ICSR).
  • Signal Detection And Benefit Risk Management: Stand up quantitative signal detection, epidemiology benchmarks, and evaluation boards; deliver faster signal triage-to-action, stronger benefit‑risk assessments, and documented decisions for regulators.
  • Aggregate Reporting And Risk Management Plan Excellence: Industrialize Periodic Benefit‑Risk Evaluation Reports (PBRER)/PSUR and Development Safety Update Reports (DSUR), plus REMS/RMP governance; standardize calendars, templates, and reviews; reduce queries and cycle time.
  • PV Governance, QPPV, And SDEA Oversight: Establish global pharmacovigilance governance, Qualified Person for Pharmacovigilance (QPPV) system, and Safety Data Exchange Agreements (SDEAs); strengthen vendor and affiliate oversight, audits, and inspection readiness.

Connect with the right consultant

Umbrex rapidly connects you with independent professionals who combine top‑tier consulting experience at firms such as McKinsey, Bain, Boston Consulting Group with hands‑on roles.

Find a consultant in our Innovator Pharmaceuticals Practice

Prefer email? Write to [email protected]